FONAR Corporation (FONR) 股票分析

公司概述

FONAR Corporation is a specialized entity within the healthcare sector that focuses on the design, manufacturing, and servicing of magnetic resonance imaging (MRI) scanners used for diagnosing human diseases and medical conditions in the United States. Operating within the diagnostics and research industry, the company provides essential medical technology infrastructure for identifying abnormalities and injuries through advanced imaging solutions. The company currently maintains a market capitalization of $117.26 million and employs a workforce of 535 individuals to support its operations and service commitments. With annual revenue reaching $106.03 million, these valuation metrics indicate that FONAR is a small-cap enterprise with a relatively modest revenue footprint compared to large-scale medical device conglomerates, suggesting a niche market position rather than broad market dominance.

财务健康

The company reported a trailing twelve-month revenue of $106.03 million, generating a net income of $7.19 million and an EBITDA of $15.05 million, which highlights a significant disparity between gross earnings before interest and taxes and the final bottom line. This gap between revenue and net income reveals a cost structure where operating expenses, taxes, and interest obligations consume approximately 32.8% of the EBITDA, significantly impacting the final profit retained by shareholders. Free cash flow stands at $2.44 million, indicating that while the company generates positive cash flow from operations, it faces substantial capital expenditure or working capital requirements that limit its immediate financial flexibility for large-scale acquisitions. The gross margin is reported at 40.8%, reflecting a healthy ability to cover the direct costs of producing MRI scanners, while the operating margin of 11.7% and profit margin of 7.1% demonstrate the efficiency of the company's overhead management and overall profitability. On the balance sheet, total cash reserves of $53.10 million exceed total debt obligations of $39.80 million, yet the debt-to-equity ratio of 24.44 suggests a leveraged capital structure where equity financing is relatively limited compared to debt usage. The current ratio of 10.00 indicates an exceptionally strong short-term liquidity position, as current assets are ten times greater than current liabilities, providing a robust buffer against short-term obligations. Return on equity is 6.0% and return on assets is 3.2%, metrics that suggest management effectiveness is moderate given the small scale of the asset base and equity capital deployed.

估值评估

FONAR Corporation carries a trailing P/E ratio of 16.18, while the forward P/E is not available, implying that analysts may lack sufficient confidence in projecting next year's earnings or that future earnings growth is too uncertain to establish a meaningful forward multiple. The price-to-book ratio is 0.69, indicating that the market values the company at less than its net asset value, which often suggests a market discount relative to the tangible book value of its MRI equipment and facilities. Alternative valuation metrics such as the price-to-sales ratio of 1.11 and an EV/EBITDA of 6.29 provide context for the company's valuation relative to its sales volume and earnings power, suggesting a low multiple environment typical of small-cap medical device firms. The stock has traded between a 52-week low of $12.00 and a 52-week high of $18.86, meaning the current market price sits within this established range but does not currently trade at the extreme highs or lows. The beta value of 0.99 indicates that the stock's price volatility moves in lockstep with the broader market, exhibiting neither significant defensive characteristics nor aggressive growth-driven fluctuations.

Growth & Income

Revenue growth year-over-year is 2.4%, while earnings growth year-over-year is 1.1%, indicating that earnings are expanding at a slower pace than revenue, which implies that cost pressures or margin compression are currently outpacing top-line expansion. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, signifying that the firm retains all of its net income to fund operations, research and development, or debt reduction rather than distributing cash to shareholders. This reinvestment strategy aligns with the typical lifecycle of a company in the diagnostics sector that prioritizes capital allocation for technology updates over shareholder income distributions. Overall, the growth and income profile presents a modest expansion trajectory with no current income generation for investors, relying instead on potential future market share gains and margin improvements to drive value.